文献速递性腺与生殖内分泌糖尿病垂体与肾上腺疾病

特纳综合征的基因组新认识与临床诊疗挑战

New genomic understanding and challenges in clinical care of Turner syndrome.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-09-25

本文综述特纳综合征的临床特征与多组学研究进展。该病为女性X染色体完全或部分缺失,发病率约50/10万(1/2000),诊断中位年龄15岁,并发症多且死亡率升高。综述强调多学科管理、生长促进治疗及性激素替代,并提出多组学有望指导新治疗策略。

要点

  • 特纳综合征发病率约1/2000女性,诊断中位年龄15岁,延误诊治常见。
  • 临床涉及矮身材、高促性腺激素性性腺功能减退、先天心脏病及内分泌代谢病等。
  • 儿童期用生长促进治疗,晚童年起推荐女性性激素替代至少至平均绝经年龄。

核心结论

  • 特纳综合征为女性X染色体完全或部分缺失所致,发病率约50/10万(1/2000),并发症广、死亡率升高。
  • 诊断中位年龄15岁,延误咨询与治疗;多学科管理、生长促进及性激素替代是当前核心策略。
  • 临床特征与多组学研究进展有望带来新认识并指导新治疗策略。

研究设计与样本

  • 综述类文章,汇总特纳综合征临床特征与多组学研究进展。

主要发现

  • 临床特征包括矮身材、高促性腺激素性性腺功能减退、卵巢发育不良、青春期延迟、不孕、先天性心脏病、内分泌疾病(含自身免疫病和2型糖尿病)、听力问题及神经认知缺陷。
  • 与一般人群相比,特纳综合征患者发病率和死亡率升高。
  • 诊断中位年龄为15岁,导致许多病例延误适当咨询和治疗。

关键数值与推荐

  • 发病率约50/10万(1/2000)女性个体。
  • 诊断中位年龄15岁。
  • 儿童期和青春期使用生长促进治疗;晚童年至至少平均绝经年龄推荐女性性激素替代。

临床怎么用

  • 采用多学科方法优化诊疗,以降低升高的发病率和死亡率并改善生活质量。
  • 儿童期和青春期考虑生长促进治疗,晚童年起至至少平均绝经年龄推荐性激素替代。
  • 关注矮身材、性腺功能减退、心血管、内分泌代谢、听力及神经认知等多系统评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Turner syndrome is a sex chromosome abnormality in female individuals characterised by the complete or partial loss of one X chromosome in all or some cells. It is a rare genetic condition occurring in approximately 50 per 100 000 (1 in 2000) female individuals. Turner syndrome is associated with a wide range of clinical characteristics including short stature, hypergonadotropic hypogonadism, ovarian dysgenesis, delayed puberty, infertility, congenital heart disease, endocrine disorders (including autoimmune conditions and type 2 diabetes), hearing problems, and neurocognitive deficits. Morbidity and mortality are increased compared with the general population. Median age at diagnosis is 15 years, delaying appropriate counselling and treatment in many cases. Growth promoting treatment is used during childhood and adolescence, while female sex hormone substitution is recommended from late childhood until at least the average age of menopause. A multidisciplinary approach is essential for optimal care, with the aim of reducing the increased morbidity and mortality and improving quality of life among women with Turner syndrome. We review advances in the clinical characterisation and multiomics of Turner syndrome, which should lead to new insights and inform new treatment strategies for individuals with Turner syndrome.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Gravholt CH, Balle CM, Hasselholm EB, et al. New genomic understanding and challenges in clinical care of Turner syndrome. Lancet Diabetes Endocrinol. 2026. PMID: 42790437. doi:10.1016/S2213-8587(26)00192-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。